These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16085545)

  • 21. Selective inhibition of primary acute myeloid leukaemia cell growth by lovastatin.
    Newman A; Clutterbuck RD; Powles RL; Millar JL
    Leukemia; 1994 Feb; 8(2):274-80. PubMed ID: 8309251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
    Wisniewski D; Strife A; Arlin Z; Knowles R; Lambek C; Gulati S; McHendry B; McKenzie S; Clarkson B
    Leukemia; 1989 Jun; 3(6):446-52. PubMed ID: 2657231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human myelomonocytic and monoblastic leukaemic cells.
    Hassan HT; Rees JK
    Hematol Oncol; 1988; 6(1):39-45. PubMed ID: 3422632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis.
    Ysebaert L; Chicanne G; Demur C; De Toni F; Prade-Houdellier N; Ruidavets JB; Mansat-De Mas V; Rigal-Huguet F; Laurent G; Payrastre B; Manenti S; Racaud-Sultan C
    Leukemia; 2006 Jul; 20(7):1211-6. PubMed ID: 16688229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell viability of acute myeloid leukaemia blasts in culture correlates with treatment outcome.
    Maha A; Cheong SK; Leong CF; Seow HF
    Hematology; 2008 Feb; 13(1):13-20. PubMed ID: 18534060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia.
    Dow LW; Dahl GV; Kalwinsky DK; Mirro J; Nash MB; Roberson PK
    Blood; 1986 Aug; 68(2):400-5. PubMed ID: 3460647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi.
    Ullah K; Ahmed P; Raza S; Satti TM; Chaudhry QU; Akhtar F; Kamal MK; Akhtar FM; Khan B
    J Pak Med Assoc; 2007 Sep; 57(9):434-9. PubMed ID: 18072636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth of CD34+ acute myeloblastic leukemia colony-forming cells in response to recombinant hematopoietic growth factors.
    Carlo-Stella C; Mangoni L; Almici C; Frassoni F; Fiers W; Rizzoli V
    Leukemia; 1990 Aug; 4(8):561-6. PubMed ID: 1697011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitation of chemosensitivity in acute myelocytic leukaemia.
    Lihou MG; Smith PJ
    Br J Cancer; 1983 Oct; 48(4):559-67. PubMed ID: 6578837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of residual disease in acute myeloid leukemia using light density gradients and culture assay.
    Ciaudo M; Marie JP; Ifrah N; Thevenin D; Zittoun R
    Pathol Biol (Paris); 1988 Jan; 36(1):67-71. PubMed ID: 3283676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of myeloperoxidase containing blast cells in acute myelogenous leukaemia.
    Advani SH; Hegde UP; Iyer RS; Gopal R; Saikia TK; Pai SK; Nair CN; Kurkure PA; Pai VR; Nadkarni KS
    Indian J Med Res; 1993 Feb; 98():8-14. PubMed ID: 8388366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy of adult acute nonlymphoblastic leukaemia.
    Jacobs P; Martell RW; Wilson EL
    Haematologia (Budap); 1990; 23(1):27-40. PubMed ID: 2204594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukaemia.
    Preisler HD; Banavali SD; Yin M; Venu G; Li YQ; Gaskins F; Raza A
    Eur J Cancer; 1994; 30A(10):1511-6. PubMed ID: 7833110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tracing the origins of relapse in acute myeloid leukaemia to stem cells.
    Shlush LI; Mitchell A; Heisler L; Abelson S; Ng SWK; Trotman-Grant A; Medeiros JJF; Rao-Bhatia A; Jaciw-Zurakowsky I; Marke R; McLeod JL; Doedens M; Bader G; Voisin V; Xu C; McPherson JD; Hudson TJ; Wang JCY; Minden MD; Dick JE
    Nature; 2017 Jul; 547(7661):104-108. PubMed ID: 28658204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
    Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
    Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
    Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
    Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.